PARK2 variability in Polish Parkinson’s disease patients - interaction with mitochondrial haplogroups

• Published in: Parkinsonism & related disorders 2012-06, Vol.18 (5), p.520-524
• Main Authors: Gaweda-Walerych, Katarzyna, Safranow, Krzysztof, Jasinska-Myga, Barbara, Bialecka, Monika, Klodowska-Duda, Gabriela, Rudzinska, Monika, Czyzewski, Krzysztof, Cobb, Stephanie A, Slawek, Jaroslaw, Styczynska, Maria, Opala, Grzegorz, Drozdzik, Marek, Nishioka, Kenya, Farrer, Matthew J, Ross, Owen A, Wszolek, Zbigniew K, Barcikowska, Maria, Zekanowski, Cezary
• Format: Article
• Language: English
• Subjects: Adult; Age of Onset; Aged; Aged, 80 and over; Chi-Square Distribution; DNA-Binding Proteins - genetics; Female; Gene Frequency; Genetic Association Studies; Haploidy; Humans; Male; Middle Aged; Mitochondrial clusters; Mitochondrial Proteins - genetics; Mitochondrial transcription factor A (TFAM); Neurology; PARK2; Parkinson Disease - epidemiology; Parkinson Disease - genetics; Parkinson’s disease risk factors; Poland - epidemiology; Polymorphism, Genetic - genetics; Transcription Factors - genetics; Ubiquitin-Protein Ligases - genetics; Young Adult
• ISSN: 1353-8020; 1873-5126
• DOI: 10.1016/j.parkreldis.2012.01.021

Abstract Aims and objectives A new pathomechanism of Parkinson’s disease (PD) involving regulation of mitochondrial functions was recently proposed. Parkin complexed with mitochondrial transcription factor A (TFAM) binds mtDNA and promotes mitochondrial biogenesis, which is abolished by PARK2 gene mutations. We have previously shown that mitochondrial haplogroups/clusters and TFAM common variation influenced PD risk. We investigate the role of PARK2 polymorphisms on PD risk and their interactions with mitochondrial haplogroups/clusters as well as with TFAM variability. Methods 104 early-onset PD patients (EOPD, age at onset ≤50 years) were screened for PARK2 coding sequence changes including gene dosage alterations. Three selected PARK2 polymorphisms (S167N, V380L, D394N) were genotyped in 326 PD patients and 315 controls using TaqMan allelic discrimination assay. Results PARK2 screen revealed two heterozygous changes in two EOPD patients: exon 2 deletion and one novel synonymous variation (c.999C > A, P333P). In association study no differences in genotype/allele frequencies of S167N, V380L, D394N were found between analyzed groups. Stratification by mitochondrial clusters revealed higher frequency of V380L G/G genotype and allele G in PD patients, within HV cluster ( p  = 0.040; p  = 0.022, respectively). Moreover, interaction between genotypes G/G V380L of PARK2 and G/G rs2306604 of TFAM , within HV cluster was significant (OR 2.05; CI 1.04–4.04; p  = 0.038). Conclusions Our results indicate that co-occurrence of G/G V380L PARK2 and G/G rs2306604 TFAM on the prooxidative HV cluster background can contribute to PD risk. We confirm low PARK2 mutation frequency in Polish EOPD patients.